TABLE 1.
Tumor growth ratesa
| Protocol and treatment | Mean tumor vol (mm3) ± SEM | Mean growth rate ± SEM (mm3/day) | % growth inhibition | Delay in tumor growth (days) |
|---|---|---|---|---|
| First protocol | ||||
| Control siRNA-C4HD | 516.7 ± 67.1* | 23.1 ± 1.5* | ||
| ErbB-2-siRNA-C4HD | 237.1 ± 50.1# | 11.2 ± 0.9# | 54.1b | 7b |
| ErbB-2-siRNA-C4HD-hErbB-2ΔNLS | 218.7 ± 55.5# | 10.2 ± 1.6# | 57.6b | 7b |
| Second protocol | ||||
| C4HD | 491.8 ± 64.0* | 32.1 ± 3.5* | ||
| C4HD-hErbB-2ΔNLS | 123.1 ± 21.8# | 8.5 ± 1.0# | 74.9c | 6.5c |
a
Growth rates were calculated as the slopes of growth curves. In the first protocol, volume, percentage of growth inhibition, and delay in tumor growth (days) in tumors from mice injected with ErbB-2-siRNA-C4HD or ErbB-2-siRNA-C4HD-hErbB-2ΔNLS cells with respect to mice injected with control siRNA-C4HD cells were calculated at day 32, as described in Materials and Methods. In the second protocol, comparisons between tumors that developed from C4HD-hErbB-2ΔNLS and C4HD cells were performed at day 20. # versus *, P < 0.001.
b
With respect to control siRNA cells, for growth inhibition, P < 0.001.
c
With respect to C4HD cells, for growth inhibition, P < 0.001.